GaiaCell actively participated in the Global Regenerative Medicine Congress 2026, held in Berlin from January 8-10. The congress gathered more than 3,000 experts from around the world, including leading researchers, clinicians, and pharmaceutical industry representatives.
At the congress, we presented the latest results of our clinical studies on the use of MSC cells in osteoarthritis and chronic wounds. Our data showed statistically significant improvement in both indications, attracting considerable interest from the international professional community.
In addition to clinical results, we presented our manufacturing innovations, including automated processes for GMP production of MSC cells. This automation enables greater consistency between batches, reduces the risk of human error, and increases production capacity.
The congress was also an excellent opportunity for establishing new partnerships. We held several meetings with potential strategic partners from the pharmaceutical industry, academic institutions, and regulatory bodies.
GaiaCell remains committed to active participation in the international scientific community. Attendance at such congresses allows us to stay in touch with the latest advances in regenerative medicine.